How is it possible... ...that we sent people to the moon almost 50 years ago, yet millions of people with tuberculosis are still treated with old, inadequate medicines? https://tbsummit.msfaccess.org/
Vacancies TOR - Point-of-Care Ultrasound Project Coordinator (Closing date: 27 March 2019) TOR - Medical Innovation and Access Policy Adviser, Access Campaign (Closing date: 24 March 2019) Stay updated Sign up to stay updated and find out how you can get involved. Email Address Data protection consent I want to receive emails from MSF and I have read and agree with the privacy policy. Read, watch, share Filter by - Any -CampaignEventsFact sheetFeature storyInfographicInterviewIssue briefLetterNewsletterOpinion articlePhoto storyPress releaseReportReport seriesResearch articleSpeechSpotlightStatementStoryTechnical briefThe issuesTopic overviewVideo Feature story Feature story | 31 December 2018 Our wishlist for 2019 3 min Issue brief | 07 May 2018 Access Campaign Year in Review 2017 Intellectual property and trade #HandsOffOurMeds Learn more Video Video | 22 March 2019 Tuberculosis TB: New drugs, new hope Technical brief Technical brief | 11 March 2019 Hepatitis C MSF Access Campaign analysis of the MPP Licence Agreement with AbbVie for glecaprevir/pibrentasvir (G/P) Opinion article Opinion article | 07 March 2019 Research and development Norway Norway has invested 200 million euros in epidemic preparedness, but are they getting what they’re paying for? 5 min Technical brief | 07 March 2019 Hepatitis C MPP licence agreement with AbbVie for glecaprevir/pibrentasvir Letter Letter | 05 March 2019 Research and development Open letter to CEPI Board Members: Revise CEPI's access policy Load More
Technical brief Technical brief | 11 March 2019 Hepatitis C MSF Access Campaign analysis of the MPP Licence Agreement with AbbVie for glecaprevir/pibrentasvir (G/P)
Opinion article Opinion article | 07 March 2019 Research and development Norway Norway has invested 200 million euros in epidemic preparedness, but are they getting what they’re paying for? 5 min
Technical brief | 07 March 2019 Hepatitis C MPP licence agreement with AbbVie for glecaprevir/pibrentasvir
Letter Letter | 05 March 2019 Research and development Open letter to CEPI Board Members: Revise CEPI's access policy
